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Abstract Inappropriate antigen presentation by the antigen-
presenting cells (APCs) is a cause of various diseases. One of the
ways to combat these diseases is to immobilize the APCs near the
infected tissue or a tissue which is susceptible to an antigen. The
antigen is presented by the APCs present in the immobilized form
on an implant and these upon binding to TH-cells result in
triggering of a cascade of events as part of the natural immune
response leading to the destruction of the antigen. This system
has been modeled as a dialysis bag containing immobilized
receptors inside the bag and the ligand diffusing out of the bag.
The simulations show that by using the implant, the concentra-
tion of the ligand that has diffused into the tissue matrix can be
substantially reduced and by suitably choosing the coupler size,
the TH-cells can also effectively be activated. ß 2002 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
In the immune response of animals, the helper T-cells (TH-
cells) are activated by interactions with the antigen-presenting
cells (APCs) through the formation of an immunological syn-
apse. These APCs internalize the foreign body and present the
peptides of the foreign bodies on their surfaces using major
histocompatibility complexes (MHCs). The APCs can be of
di¡erent types, and comprise primarily of macrophages and
dendritic cells. The TH-cells bind to these APCs and stimulate
the B-cells, and/or TH- and TC-cells by mediating the response
through a chain of mediators called cytokines. In the end, the
foreign body is destroyed or it is neutralized. If the foreign
body is a virus, which has infected a host cell, TH-cells recog-
nize it and initiate a cascade of events leading to the destruc-
tion of the infected cells [1].
However, in many diseases, TH-cells fail to activate in re-
sponse to antigen or are inappropriately activated. Many of
such diseases occur due to inappropriate antigen presentation
by the APCs either due to defective APCs or due to a low
APC concentration in the plasma. These include genetic dis-
orders [2,3], viral infections [4,5], and cancer [6,7]. One means
to combat these diseases is to present MHC peptide in the
a¡ected region so that the TH-cells can bind to these sites and
stimulate the immune response. Another way is to immobilize
the APCs (speci¢cally primed against an antigen) on a poly-
mer support and implant it in the vicinity of the concerned
tissue. In this case, the antigen will bind to these APCs. This
treatment strategy is therefore able to provide normal (and
e¡ective) APCs in adequate concentrations (or counts) in the
region of the body that is vulnerable to a speci¢c antigen. The
TH-cells present in the bloodstream identify these MHC pep-
tides and bind to them, and thereafter the natural immune
response of the body takes over and does the needful to ef-
fectively destroy the antigen source of the infection or the
disease.
In case of antigens like virus or toxic compounds produced
by bacteria, there is a competition between the binding to the
APCs (and subsequent endocytosis) and their di¡usion into
the tissue. The di¡usion of the antigen may be across the
bloodstream or into the tissue matrix [8] depending on the
speci¢c location of the disease-causing antigen. Therefore,
the implant must be designed such that the free antigen con-
centration is extremely small, at least until the natural im-
mune response takes over. The local region where implant is
present can be modeled as an immobilized receptor system
(immobilized APCs involving receptor-mediated antigen bind-
ing, on a polymer matrix) in a dialysis bag (tissue) containing
free ligand in the medium (antigen). In this paper, we have
modeled the implant system to study the response and have
attempted to estimate the size of the coupler (e.g. PEG^biotin)
for immobilizing the receptors in order to achieve the objec-
tive. We also expect to study the feasibility of this idea and
thus determine the constraints on the applicability of this
technique. The analysis is believed to be helpful in the design
of such implants for tackling a variety of diseases.
Previous works on T-cell activation and its modeling [9^15]
have studied interactions between the T-cell receptors (TCRs)
and the ligands in solution but this is the ¢rst study of its kind
in which an immobilized receptor has been considered with
respect to the physiological-like situations. Therefore, in the
absence of any experimental observations available for the
analysis, representative parameter values have been taken
from T-cell^MHC peptide binding assuming that the interac-
tions are similar. Even though these are two di¡erent systems,
however, an analysis with representative parameter values can
provide an insight into the process. Moreover, some of the
assumptions in previous analysis [10], like ligand concentra-
tion being much more than the receptor concentration, are
not necessarily valid under physiological conditions. In fact,
the receptor concentration may be much more than the ligand
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concentration in case of immobilized systems like the implant
we are studying in this paper.
2. Modeling and mathematical analysis
The modeled system has been considered as a dialysis bag in a
dialysis chamber. The dialysis bag contains immobilized receptors
and free ligand, which can either bind to the receptors or di¡use
out of the dialysis bag. The valency of ligand, which corresponds to
the maximum number of bonds a ligand can form with receptors, has
been taken as four for our analysis. A valency of four has been chosen
to demonstrate multivalency, though the trends observed for other
valencies of the ligands are similar. The tetravalent ligand means
that for e¡ective antigen binding to the APCs, it is desirable to
have tetramerically bound receptor^ligand complex. Therefore, we
concentrate only on those receptors which have the capability to result
in tetravalent binding. Since the receptor distribution is random, we
can consider Poisson distribution. The immobilization surface can be
divided into spheres each of volume Vs such that the radius of the
sphere is described as access radius, r [16]. Access radius can be
considered as the distance from the center, which a receptor can
traverse and bind to ligand molecule. Based on Poisson distribution,
probability of k receptors in a sphere,
Pk  Rimmtot V sNak=k!Wexp3Rimmtot V sNa 1
where Rimmtot is the total concentration of the immobilized receptor and
Na is Avogadro’s number. Since we are concerned about spheres with
four or more receptors, the total receptor concentration for tetrava-
lent binding is given as
Rtetratot  Rimmtot 134Rimmtot V sNai=i!Wexp3Rimmtot V sNa 2
where summation is for i = 0, 1, 2 and 3. For the analysis of receptor^
ligand binding, we have used the following notation:
L = total ligand concentration in the dialysis bag (mol l31)
LF = free ligand concentration inside the dialysis bag (mol l31)
K= permeability of the bag material (h31)
Lout = ligand concentration outside the bag (mol l31)
Lbound = total bound ligand concentration (mol l31)
KX = cross-linking constant (l mol31)
KD = dissociation constant (mol l31)
R0 = free receptor concentration (mol l31)
Li = LiR complex with i sites bound (mol l31)
v = valency of ligand (dimensionless)
The receptor^ligand binding may be considered to occur as shown
in Fig. 1. Since all the receptors immobilized and present on the
polymer matrix see a common ligand concentration equal to the
bulk concentration inside the dialysis bag, irrespective of their pres-
ence in any particular sphere, we have
Rtetratot  R0f1 vLF=KDW1 KXR0v31g 3
and
Li  vCiLFR0i=KDWKi31X 4
These equations have been obtained by considering that rate of re-
ceptor^ligand binding is high compared to any other process occur-
ring in the system. Therefore, the binding can be assumed to be at
quasi-equilibrium. Li in Eq. 4 corresponds to the amount of ligand
with i sites bound to receptors in spheres with four or more receptors,
and R0 is the concentration of unbound receptor in the same spheres.
These relations have previously been obtained for general receptor
binding by multivalent ligands and have been applied to the release
of histamine from basophils [9]. This model has frequently been used
to describe various other situations like receptor clustering induced by
incubation of T-cells with MHC peptide oligomers [10], a response
which requires receptor cross-linking [11], IgE^FM receptor clustering
[12], dissociation of insulin and nerve growth factor from their cross-
linked receptors [13], viral attachment to cell surface receptors [14],
and dimeric MHC peptide complexes binding to CD8 T-cells [15].
However, we would like to point out that under in vivo conditions,
the interactions might be di¡erent due to the reasons mentioned ear-
lier. Thus from Eq. 3, we get
LF  1=vWRtetratot =R031WKD=1 KXR0v31 5
From Eq. 4, we can determine the total amount of ligands bound to
the receptors present in spheres with at least four receptors, Ltetrabound.
Ltetrabound  4Li
 4vCiKXi31LF=KDWR0i
 LF=KDKXW4vCiKXR0i
 LF=KDKX1 KXR0v31
 1=vKXWRtetratot =R031W1 KXR031=
1 KXR0v31 6
obtained by substituting for [LF] using Eq. 5. For dialysis through a
dialysis bag, the £ux is proportional to the concentration gradient or
dL=dt  3K WLF3Lout 7
Lout can now be obtained by carrying out a mass balance over ligand.
Taking the volumes of the dialysis bag (or the microenvironment
around the implant) as Vin and of the dialysis chamber (or the tissue)
as Vout,
V inLtot  V inLF  Lbound  VoutLout 8
Since we intend to maximize the tetramerically bound receptor^ligand
complex, it is important to select the access radius such that [Rtetratot ] is
very large compared to the other possibilities of spheres with one, two
or three receptors. Therefore, in order to obtain [Rtetratot ] equal to at
least, say, 90% of [Rimmtot ], we must choose the access radius suitably
using Eq. 2. As a consequence of this design constraint, the amount of
ligand bound to the receptors present in spheres with less than four
receptors will be very small compared to those bound by the receptors
present in spheres with at least four receptors, i.e. [Lbound]W[Ltetrabound].
Hence,
Lout  Ltot3LF3LtetraboundWV in=Vout 9
Therefore, using Eqs. 7 and 9, we have
dL=dt  3Kf1=vWRtetratot =R031WKD=1 KXR0v313V in=VoutW
Ltot31=vWRtetratot =R031WKD=1 KXR0v3131=vKXW
Rtetratot =R031W1 KXR031=1 KXR0v31g 10
Since [L] = [LF]+[Lbound], we have that d[L]/dt = d[LF]/dt+d[Lbound]/
dt = (d[LF]/dR0+d[Lbound]/dR0)WdR0/dt, or Eq. 10 becomes
dR0=dt  3Kf1=vWRtetratot =R031WKD=1 KXR0v313V in=VoutW
Ltot31=vWRtetratot =R031WKD=1 KXR0v3131=vKXW
Rtetratot =R031W1 KXR031=1 KXR0v31g=fKD=vW
3Rtetratot =R20=1 KXR0v31  Rtetratot =R03113vKX=
1 KXR0v  1=vKXW3Rtetratot =R20Wf1 KXR031=
1 KXR0v31g  Rtetratot =R031fKX313vKX=1 KXR0vgg
11
Eq. 11 can be solved numerically to determine R0 under a speci¢c set
of conditions and thereafter concentrations of free and various bound
forms, and also of the ligand present outside the dialysis bag, can be
calculated. However, for the purpose of the design of our implant, we
have analyzed the concentrations of tetravalent receptor^ligand com-
plex, and the ligand present outside the dialysis bag, which corre-
sponds to the antigen that has di¡used into the tissue. The initial
condition for solving Eq. 11 is that the total ligand concentration in
the dialysis bag at t = 0 equals the total ligand concentration when the
ligand was added, i.e. ([LF]+[Lbound])Mt0 = Ltot.
3. Simulations
All the simulations were carried out using Mathematica 4
(Wolfram Research). Simulations were carried out for a ¢xed
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receptor concentration and di¡erent ligand concentrations in
the system. The time variations in the antigen concentration in
the tissue, which corresponds to the ligand outside the dialysis
bag, were obtained and analyzed. This was done in the pres-
ence and the absence of the implant to understand the con-
straints on the implant. In addition, the concentration of the
immobilized receptor, which exists in tetramerically bound
receptor^ligand complex form, was also determined. The
amount of this complex may be expected to dictate the
T-cell activation by the body itself. The parameter values
used for the simulations are as shown in Table 1. The values
taken were the typical values available in literature for di¡er-
ent T-cell clones [10] and dialysis systems [17]. As mentioned
earlier, it has been assumed, for the sake of analysis, that
T-cell binding to MHC peptide is similar to the antigen bind-
ing to the APC surface receptors. It was assumed that the
implant contains 0.1 WM receptor concentration as high con-
centrations can be achieved by immobilization, and even high-
er than what has been taken may be achievable. The ligand
concentrations were taken to cover a wide range from 1 nM
to 1 WM for comparison between the response with and with-
out the implant (Fig. 2). However, for the determination of
the tetravalently bound receptor concentration, the ligand
concentration was taken as 10 nM (Fig. 3).
4. Results and discussion
The ¢rst step towards the designing of the implant involves
the determination of the coupler length and as discussed pre-
viously, coupler length can be chosen such that the majority
of receptors have the ability to form tetravalent binding with
the ligand, as desired for the T-cell activation process. For a
receptor concentration of 0.1 WM, which has been taken for
all simulations, Eq. 2 gives that the coupler length should be
at least 300 nm. This access radius is obtained by ¢rst deter-
mining the Vs such that Rtetratot is 0.9R
imm
tot , for a given value of
Rimmtot . With this coupler length, more than 90% of the recep-
tors are expected to be able to bind tetravalently. The coupler
length can be controlled by using di¡erent means like strep-
tavidin^biotin^PEG chain used for immobilization of the re-
ceptor to the polymer base.
The comparison of di¡used ligand concentration for di¡er-
ent initial ligand concentrations in the dialysis bag reveals that
presence of the implant results in a drastic drop in [Lout] even
after long intervals of a few hours. As seen in Fig. 2a,b, after
1 h, the presence of implant leads to a di¡used ligand con-
centration nearly an order of magnitude lower than what it is
in the absence of the implant. However, when the ligand con-
centration is extremely high and is about an order of magni-
tude higher than the immobilized receptor concentration, we
do not observe any signi¢cant di¡erence between the di¡used
ligand concentrations in the presence or absence of the im-
plant (Fig. 2c).
The analysis of the tetravalently bound receptor concentra-
tion shows that more than 12% of the immobilized receptors
exist in the tetravalently bound form (Fig. 3). These bound
Fig. 1. Kinetic scheme showing various stages in receptor^ligand binding. The ligand used here has a valency v. Li denotes the receptor^ligand
complex with i ligand sites bound to the receptors.
Table 1
Parameter values used for the simulations for modeling the APC^
antigen binding in the vicinity of a tissue
Parameter Value
KX 5U107 M31
KD 1.7U1036 M
Vin/Vout 0.1
v 4
K 1.5 h31
Fig. 2. Comparison of time variation of di¡used ligand concentra-
tions outside the dialysis bag in the presence and absence of immo-
bilized receptor (or implant). Di¡erent ligand concentrations have
been studied: (a) 1 nM, (b) 10 nM, and (c) 1 WM.
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receptors play an important role in the T-cell activation in
order to destroy the antigen as the APCs are able to tightly
bind the antigen and after internalization, they can be suitably
presented on the surface. The T-cells forming TCR synapse
release cytokines into the bloodstream and thereby result in
activation of the immune response. Once the T-cells have been
activated, the mediators can activate di¡erent components of
the immune system like TH-cells, B-cells and TC-cells and
along with various agents like macrophages, the antigen can
be destroyed by the body itself. The activation of the immune
response also ensures that the antigen is ‘stored in memory’ so
that if the body encounters the same antigen again, it can be
neutralized or destroyed immediately. Even in case of a high
ligand concentration, though we do not observe any signi¢-
cant reduction in di¡used ligand concentration, the amount of
tetravalently bound receptor is as high as 15^20% of the
immobilized receptor concentration. Again this results in
T-cell activation and the cascade of events comprising im-
mune body’s immune response. Based on the fraction of the
tetramerically bound receptors, suitable immobilized receptor
concentrations as well as the coupler length may be taken
to avoid any dose^response-related negative e¡ect, if any
(as the amount of antigenic peptide sequence displayed by
the APC correlates directly with the tetramerically bound
ligand).
Based on these results, we ¢nd that the presence of the
polymer implant with immobilized APCs can e¡ectively con-
trol the spread of antigen and its passage into the tissues. The
implant, however, cannot be expected to replace the immune
system completely but plays an important role during the
initial stages which is the most crucial period for combating
an infection. From the analysis of the model and considering
the Poisson distribution of receptors on polymer surface, we
can design an e¡ective implant with desired properties. In this
case, we studied a tetravalent ligand but there are a variety of
ligands in nature and using similar analysis, a suitable implant
can be designed. Similarly, to mimic the physiological scenar-
io, appropriate APC loading on the polymer implant may also
be determined and used. The presence of implant being able
to reduce the antigen concentration in the tissue is also a
major advantage. This becomes even more important in cases
where the antigen concentration keeps increasing. Such situa-
tions are very common like bacteria or virus or a toxin pro-
duced by a bacteria. In such situations, the APCs reduce the
concentration of these antigens immediately and therefore, in
spite of growth of these disease-causing agents, the concen-
tration is still maintained low. In addition, before these agents
reach a dangerous limit, the body’s immune response has al-
ready been activated to take the necessary action. It should be
noted that the model does not take into account the internal-
ization of the bound antigen. However, internalization of the
antigen ensures that the concentration of the free receptors
available for binding the antigen is higher than what has
been predicted from the analysis. Therefore, the system per-
formance is expected to be better than that obtained from the
modeling.
The presence of a high concentration of APCs in immobi-
lized form provides an excellent means to activate the immune
response in those subjects who are susceptible to diseases due
to failure of or inappropriate antigen presentation by the
APCs. These implants can also be used in people who are
already su¡ering from some disease due to the same reasons.
An important point, which is brought to light from this anal-
ysis, is that these implants are highly e¡ective when the anti-
gen concentration is very low, i.e. either such implants can be
used as vaccination or can be used for the treatment when the
infection is at early stages of its development. But by suitable
modi¢cations in the system, this problem can also be tackled
easily. In order to make the implant highly e¡ective even at a
high antigen concentration, we can either increase the immo-
bilization density or increase the value of KX or decrease the
equilibrium dissociation constant, KD. These changes will sig-
ni¢cantly improve the e⁄cacy of the designed implant for a
wide range of antigen concentrations.
5. Summary
In this modeling analysis, we have modeled the arti¢cial
antigen presentation as a dialysis system containing an immo-
bilized receptor system and free ligand in the dialysis bag. The
change in ligand concentration di¡using out of the dialysis
bag has been determined for various ligand concentrations
for a ¢xed receptor concentration. The di¡used ligand corre-
sponds to the antigen that may di¡use into a tissue and the
smaller its concentration, the better it is. From the analysis,
we ¢nd that for ligand concentrations which are lower than
the receptor concentration, the di¡used ligand concentration
is nearly an order of magnitude lower than what it may be in
the absence of any implant. In addition, the amount of tetra-
merically bound receptor is signi¢cant. This tightly bound li-
gand can be easily internalized by the APCs and thus pre-
sented on their surface as MHC peptide. A signi¢cant
amount of these MHC peptides means an e¡ective T-cell ac-
tivation. However, at a very high antigen concentration, we
observe that the implant with speci¢c features may not be
suitable. However, it may be modi¢ed by changing either
the receptor density or by increasing binding a⁄nity to the
ligand. The analysis considers that the random distribution of
receptors on a polymer base can be described by Poisson
distribution and using this, the implant with desired properties
can be designed. This kind of implant may be used for vacci-
nation purposes as well as treatment of various diseases.
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Fig. 3. Variation in concentration of tetramerically bound receptor
with time at a ligand concentration of 10 nM and parameter values
as shown in Table 1.
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